KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Common Equity: 2018-2025

Historic Common Equity for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $473.0 million.

  • Twist Bioscience's Common Equity rose 0.06% to $473.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.0 million, marking a year-over-year increase of 0.06%. This contributed to the annual value of $473.0 million for FY2025, which is 0.06% up from last year.
  • Latest data reveals that Twist Bioscience reported Common Equity of $473.0 million as of Q3 2025, which was down 1.10% from $478.2 million recorded in Q2 2025.
  • Twist Bioscience's 5-year Common Equity high stood at $863.4 million for Q1 2022, and its period low was $440.1 million during Q1 2025.
  • Moreover, its 3-year median value for Common Equity was $491.1 million (2024), whereas its average is $540.6 million.
  • Per our database at Business Quant, Twist Bioscience's Common Equity skyrocketed by 132.47% in 2021 and then decreased by 25.31% in 2024.
  • Quarterly analysis of 5 years shows Twist Bioscience's Common Equity stood at $626.2 million in 2021, then increased by 19.19% to $746.3 million in 2022, then decreased by 20.94% to $590.0 million in 2023, then declined by 22.73% to $455.9 million in 2024, then increased by 0.06% to $473.0 million in 2025.
  • Its last three reported values are $473.0 million in Q3 2025, $478.2 million for Q2 2025, and $440.1 million during Q1 2025.